GT Biopharma (GTBP) had the highest return between 2017 and 2018 by a US stock in the Biotechnology Industry, returning 288,160.9%.

ASSET	YEARS	% RETURN
GT Biopharma (GTBP)	2017-2018	288,160.87%
Immatics (IMTX)	2017-2018	195,900%
AquaBounty Technologies (AQB)	2017-2018	28,372.22%
CareDx (CDNA)	2017-2018	766.9%
Arrowhead Pharmaceuticals (ARWR)	2017-2018	696.15%
Madrigal Pharmaceuticals (MDGL)	2017-2018	653.98%
Lixte Biotechnology (LIXT)	2017-2018	564.64%
Viking Therapeutics (VKTX)	2017-2018	537.5%
Vericel Corp Ord (VCEL)	2017-2018	470.49%
argenx NV ADR (ARGX)	2017-2018	436.7%
Uniqure (QURE)	2017-2018	410.99%
Renovaro Biosciences (RENB)	2017-2018	401.79%
Fate Therapeutics (FATE)	2017-2018	391.57%
EXACT Sciences (EXAS)	2017-2018	363.63%
BeiGene (ONC)	2017-2018	357.89%
Amarin (AMRN)	2017-2018	340.45%
Nutriband (NTRB)	2017-2018	317.07%
MDxHealth SA ADR (MDXH)	2017-2018	300%
AnaptysBio (ANAB)	2017-2018	298.69%
Sarepta Therapeutics (SRPT)	2017-2018	284.94%
Sangamo Therapeutics (SGMO)	2017-2018	270.32%
Avalo Therapeutics (AVTX)	2017-2018	262.92%
Esperion Therapeutics (ESPR)	2017-2018	259.38%
Galectin Therapeutics (GALT)	2017-2018	253.61%
Star Equity (STRR)	2017-2018	249.93%